
|Articles|February 1, 2005
Cytoskeletal agents: future option for reducing IOP?
New Orleans—Cytoskeletal agents, which increase outflow facility in the trabecular meshwork, are one of the drug classes that could expand the pharmaceutical options available to reduce IOP, said Carl B. Camras, MD, professor, chairman, and director of the glaucoma service, department of ophthalmology, University of Nebraska Medical Center, Omaha.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA feedback supports Azura’s Ophthalmic's planned NDA for AZR-MD-001 in MGD
2
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy
3
Argenx discontinues phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease
4
Strategic approaches optimize teaching and learning in the clinic
5












































.png)


